Accumulation of paired helical filament tau contributes to neurodegeneration in Alzheimer's disease (AD).
studying the causes and progression of AD. Indeed, clinical-pathologic studies suggest that an in vivo imaging measure of tau may be particularly informative because of the regional anatomic association of tau pathology with specific cognitive difficulties dependent in part on the compromised brain region .
New tau-binding radioligands for positron emission tomography (PET) promise to enable in vivo imaging of tau accumulation (Dani et al., 2016; Villemagne, Fodero-Tavoletti, Masters, & Rowe, 2015) . A successful PET tau tracer holds the potential to serve as an invaluable biomarker for improving AD clinical diagnoses, evaluating response to taufocused treatments, and predicting disease progression. Here we focus on the compound F-T807 (Chien et al., 2013; Zhang et al., 2012) . Autoradiography and in vitro studies have shown that 18 F-flortaucipir binds to paired helical filament forms of tau in the brains of autopsy-confirmed AD patients (Marqui e et al., 2015) . Uptake is elevated in the hippocampi and medial temporal lobes of patients with amnestic AD and MCI (Chien et al., 2013) , and the anatomical distribution of uptake parallels Braak's anatomical staging of AD pathology (Braak, Alafuzoff, Arzberger, Kretzschmar, & Del Tredici, 2006; Schwarz et al., 2016; Sch€ oll et al., 2016) .
As studies of 18 F-flortaucipir in typical, amnestic AD accrue, it is crucial to evaluate the tracer in less common dementia syndromes, characterized by different anatomical patterns of tau accumulation and by distinct patterns of cognitive impairment. Studies that focus on typical amnestic AD may be limited in their ability to discover neocortical correlates of patients' clinical symptoms; furthermore, PET studies of typical AD often include only assessments of global cognition and memory, thus neglecting potential neural correlates of other domainspecific impairments commonly observed in AD. In contrast, nonamnestic and early-onset amnestic AD syndromes are marked by lower rates of hippocampal and medial temporal lobe atrophy than typical late-onset amnestic AD, yet they have neocortical disease causing syndromes that may be confused with phenotypes due to non-AD pathology (Mendez, Lee, Joshi, & Shapira, 2012; Murray et al., 2011; Whitwell et al., 2012) . Furthermore, 18 F-flortaucipir binds differently to different tau isoforms (Lowe et al., 2016; Sander et al., 2016) , raising the the possibility that the effectiveness of this radioligand will vary among heterogeneous atypical AD patients. The validity of 18 F-flortaucipir as an in vivo measure of tau will be supported by uptake patterns which mirror postmortem tau distributions in these phenotypes, and by statistical associations with patients' cognitive performance.
Few studies to date have included non-amnestic AD cases in 18 Fflortaucipir imaging cohorts. Two recent studies Xia et al., 2017) have demonstrated anatomically distinct distributions of tracer uptake in amnestic and non-amnestic AD patients. Xia et al. (2017) further demonstrated that tracer uptake was associated with cortical thickness, an established neuroimaging marker of disease.
However, Xia et al. (2017) had insufficient power to examine associations with cognition. Ossenkoppele et al. (2016) addressed these associations with both voxelwise and region-of-interest (ROI) analyses, although their results indicated relatively modest associations with cognition: voxelwise analyses were presented at a liberal statistical threshold of p < .05 (uncorrected for multiple comparisons), and in ROI analyses of memory performance, the authors reported only a marginally-significant association in the hippocampus. Both of these studies highlight the statistical challenges imposed by studying rare atypical AD phenotypes: the relative scarcity of such patients limits researchers' ability to detect clinically-relevant associations between cognition and imaging markers.
Sparse and multivariate analysis methods can enhance sensitivity to imaging correlates of disease, particularly when the cognitive or clinical symptoms under investigation involve distributed brain networks (Avants et al., 2012 (Avants et al., , 2014a Cook et al., 2014; McMillan et al., 2014) .
Similar methods have been applied in typical amnestic AD (Tosun et al., 2017) to detect areas of 18 F-flortaucipir uptake associated with florbetapir; to our knowledge, however, the present study is the first to apply sparse multivariate methods to the analysis of tau PET imaging in atypical AD. We used sparse regression to examine voxelwise associations between 18 F-flortaucipir uptake and cognitive performance in patients with early-onset amnestic AD and two non-amnestic AD syndromes: logopenic-variant primary progressive aphasia (lvPPA) and posterior cortical atrophy (PCA). LvPPA is a neurodegenerative condition characterized by deficits in repetition and lexical access accompanied by atrophy in posterior temporal and inferior parietal cortices (Bonner, Ash, & Grossman, 2010; Gorno-Tempini et al., 2004 , 2011 . Roughly 70% of lvPPA cases are attributable to an underlying AD pathology, and the remainder are associated with frontotemporal lobar degeneration (Giannini et al., 2017; Mesulam et al., 2014a,b) . PCA is a similarly progressive condition marked by primary deficits in vision and visuospatial processing, with an anatomical basis in occipital, occipito-temporal, and parietal cortices (Crutch et al., 2012; Hof, Vogt, Bouras, & Morrison, 1997) , most often due to AD pathology Tang-Wai et al., 2004) . We predicted that 18 F-flortaucipir would bind specifically and differentially in amnestic and non-amnestic AD phenotypes, and that tracer uptake would predict patients' cognitive symptoms in multiple domains of interest.
| M A TER I A LS A N D M ETH OD S

| Patient characteristics
We recruited patients with early-onset amnestic or non-amnestic (lvPPA or PCA) AD through the Penn Memory Center and the Cognitive Neurology Clinic at the Hospital of the University of Pennsylvania.
Inclusion criteria included age of 45-70 years, a Mini-Mental Status Exam (MMSE) score higher than 10, and the presence of a reliable informant to report on the patient's cognitive status and activities of daily living. Exclusion criteria for all patients included a history of other neurological or psychiatric conditions (including stroke and major depression), head trauma, substance abuse, pregnancy, and an abnormal EKG reading. Patients underwent medical and neurological examinations, cognitive testing, and magnetic resonance imaging (MRI), and structural MRIs were screened for evidence of significant vascular disease (e.g., stroke, other infarct or hemorrhage, or small-vessel ischemic disease). One patient was excluded due to history of stroke, and a second was excluded due to an indeterminate clinical phenotype. A final total of 14 patients were included and classified according to their clinical presentation at the time of PET imaging. Of these, 4 lvPPA patients had hyperlipidemia, and 2 of the 4 additionally were hypertensive; 1 PCA patient had hyperlipidemia; 1 aAD patient had hypertension, and 1 aAD patient had hyperlipidemia. Geriatric Depression Scale (GDS) scores were available for 9/14 patients, collected at a median of 87.7 days (SD 5 153.0 days) from the time of PET imaging, with a median total score of 2.0 (SD 5 3.3). One patient reported a history of depression within the previous 2 years but was free of depression at the time of study. Informed consent was obtained from all patients or their caregivers as required by the Institutional Review Board of the University of Pennsylvania. All patients were diagnosed through clinical consensus by two or more board-certified neurologists (including DW, DI, and MG). Additional information on patient symptoms was collected from caregivers through questionnaires and structured interviews. Total scores and performance on domain-specific subscales of the Philadelphia Brief Assessment of Cognition (PBAC; Libon et al., 2011b) were used to inform clinical diagnoses. Two PCA patients and 1 aAD patient were left-handed; all other patients were right-handed.
Non-amnestic phenotypes included logopenic-variant primary progressive aphasia (lvPPA, n 5 4, according to Gorno-Tempini et al., 2011) and posterior cortical atrophy (PCA, n 5 5; Crutch et al., 2012) .
LvPPA patients were evaluated for speech production deficits using the Cookie Theft description from the Boston Diagnostic Aphasia Examination (Ash et al., 2013; Goodglass & Kaplan, 1983; Goodglass, Kaplan, & Barresi, 2001) ; detailed results are presented in the Supporting Information. Diagnostic criteria for PCA included presence of objective deficits or subjective history of disturbances in visuospatial function, preserved language and episodic memory, and absence of other neurological or psychiatric conditions. Amnestic AD (aAD, n 5 5) was diagnosed according to McKhann et al.'s (2011) criteria for probable AD. All five aAD patients had a disease onset by age 65. Two of 5 patients with aAD diagnoses at the time of this study (male, aged 62.6 years; female, aged 60.8 years) had previously presented with PCA before developing episodic memory deficits. Due to the early onset of disease and the initial appearance of non-memory symptoms in 2 patients, the aAD group should not be considered representative of a typical AD presentation; however, we hypothesized that tau PET imaging results in cortical and subcortical areas related to episodic memory would be associated with their imaging results.
Because non-amnestic AD can present as a result of frontotemporal lobar degeneration (FTLD) pathology, we required lvPPA and PCA patients to have a ratio of cerebrospinal fluid (CSF) T-tau/Ab greater than 0.34 as evidence of AD pathology; this measure effectively discriminates AD from normal cognition (area under the curve of 0.917; Shaw et al., 2009 ) and from FTLD (100% sensitivity and 90.9% specificity in an autopsy-confirmed cross-validation sample; Irwin et al., 2012) .
CSF results were unavailable for 2 aAD patients (female, aged 63.4 years; male, aged 69.5 years) who did not undergo lumbar punctures.
Both patients had undergone 
| Neuropsychological testing methods
Patients underwent a battery of cognitive assessments administered at a mean interval of 8 days (range 0-32) from the PET imaging session. (Libon et al., 2011b ). Language was assessed by patients' performance on a sentence repetition task, confrontation naming on a 30-item version of the Boston Naming Test (BNT), semantic category fluency (animals), repetition from the MMSE ("no ifs, ands, or buts"), and forward digit span. 
| Neuroimaging methods
Anatomical MRI data was collected for all patients at a mean interval of 76 days from the PET imaging session (range from 0 to 308 days; all but 2 patients were scanned within 6 months of PET imaging). MRI scans were collected on a 3-Tesla Siemens TIM Trio scanner using an 8-channel head coil, with a T1-weighted anatomical imaging protocol with a repetition time of 1620 ms, echo time of 3.09 ms, inversion time of 950 ms, axial in-plane resolution of 0.98 mm 3 0.98 mm, and 1 mm slice thickness in a matrix of 192 3 256 3 160 voxels. Images were visually inspected for artifacts, then processed with an automated MRI processing pipeline based on Advanced Normalization Tools (ANTS, http://www.picsl.upenn.edu/ANTS/; Avants et al., 2011b Avants et al., , 2014b Tustison et al., 2014) . Images were corrected for intensity inhomogeneities using a version of the N3 algorithm (Sled, Zijdenbos, & Evans, 1998) with a modified optimization scheme and fast B-spline approximation (Tustison et al., 2010) . Next, a symmetric diffeomorphic algorithm (Avants et al., 2011a; Klein et al., 2009 ) was used to spatially align images to a local neurodegenerative disease template constructed from healthy and diseased elderly brains imaged with the same scanner and acquisition parameters as the current dataset. This template was constructed from T1-weighted MRIs from 113 elderly controls and 94 neurodegenerative disease patients (AD, n 5 23; amyotrophic lateral sclerosis, n 5 14; corticobasal degeneration, n 5 10; frontotemporal dementia, n 5 25; Parkinson's disease, n 5 14; and progressive supranuclear palsy, n 5 8). Avants et al. (2011a) describes the template generation process. Images in the native acquisition space were automatically segmented into 6 tissue classes (cortical and subcortical gray matter, brainstem, cerebellum, white matter, and cerebrospinal fluid) informed by probability maps derived from the template brain (Avants et al., 2011a (Avants et al., , 2011b Pustina et al., 2016) . Group analysis was performed by aligning patients' PET data and gray matter probability maps to the template space. A gray matter mask was created by thresholding cortical and subcortical gray matter probability maps in template space to exclude voxels with less than 0.3 probability of containing gray matter.
This gray matter mask defined the set of voxels used both in sparse regression and ROI-based analyses of PET data.
PET imaging was performed on a Philips Ingenuity TF PET/CT scanner at the PET Center in the Department of Radiology of the University of Pennsylvania. An intravenous injection of 370 mBq (10 mCi 6 10%) of 18 F-flortaucipir was administered to all patients, and they were imaged in 6 frames of 5 minutes each from the period 75- Age, disease duration, and education are expressed in years. LvPPA: logopenic-variant primary progressive aphasia; PCA: posterior cortical atrophy; aAD: amnestic AD; MMSE: Mini-Mental Status Exam; A-beta: CSF amyloid-beta concentration (pg/mL); T-tau/A-beta: ratio of total tau and amyloidbeta concentrations. Means and standard deviations for each phenotype are in bold face.
105 minutes post-injection with 2 mm isotropic voxels in a 128 3 128 3 90 voxel matrix. PET data were corrected for signal attenuation, scatter, and patient head motion, then summed across the 6 acquisition frames. A rigid-body alignment was computed to register native-space PET images to each patient's accompanying T1 image. Partial volume correction was performed using the structural/functional synergy resolution recovery (SFS-RR) method of Shidahara et al. (2009) , which replaces high spatial frequencies in a static PET image with the corresponding frequencies in a high-resolution structural brain image, with supervision from a probabilistic brain atlas and appropriate scaling to adjust for differences in signal magnitude between PET and structural imaging data. Two additional voxelwise partial-volume correction methods, the reblurred Van-Cittert and discrete iterative Yang approaches (Thomas et al., 2016; Tohka & Reilhac, 2008; Yang et al., 1996) Between-group uptake differences were investigated using voxelwise 2-sample t-tests; due to the small sample sizes available for each phenotype, we used a liberal statistical threshold of p < .01, uncorrected for multiple comparisons, and a voxel clustering threshold of 100 lL.
This cluster size corresponds to 100 voxels in the template space and 12.5 voxels in the PET acquisition space. All results were subsequently warped to the MNI152 template space (Jenkinson, Beckmann, Behrens, Woolrich, & Smith, 2012) for visualization, and stereotactic coordinates are reported in this space throughout the manuscript.
Associations between cognition and tracer uptake were assessed with sparse regression, using the algorithm described by Kandel, Wolk, Gee, and Avants, (2013) . Sparse analysis methods are effective for datasets in which the number of predictor variables (i.e., voxels) greatly exceeds the number of observations (i.e., patients), making it challenging to determine a unique set of predictors, and increasing the risk of overfitting a statistical model. Sparse methods apply a penalty (in this case, an ' 1 parameter) to exclude predictors that have only weak associations with the outcome variable; the final model solution consists of one or more eigenvectors, or sets of covarying voxels which optimally predict the outcome variable. In the approach of Kandel et al. (2013) , the eigenvector solution is subject to a minimum cluster size threshold, which helps to ensure that voxels in the solution are clustered in an anatomically-plausible manner; as well as a sparsity parameter, which determines the maximum proportion of voxels with non-zero coefficients (and thus prevents the algorithm from using all available voxels to overfit a model). Sparsity and cluster size parameters were chosen by determining which combination of values produced the lowest prediction error for modeling patients' age, which was uncorrelated with the cognitive predictors of interest. On this basis, a sparsity of 0.001 and cluster threshold of 100 lL were chosen for modeling patients' language, visuospatial, and memory performance.
Input data for each model consisted of whole-brain SUVR values converted to an n 3 m data matrix, where n 5 the number of partici- 
| Hypotheses and predictions
On episodic memory tasks, aAD patients were expected to perform worse than both PCA and lvPPA patients. LvPPA patients were expected to demonstrate worse language performance than the other two patient groups. Similarly, we predicted PCA patients would perform worse on visuospatial tasks than lvPPA patients and aAD patients.
Based on published criteria for imaging-assisted diagnosis of lvPPA (Gorno-Tempini et al., 2004 , 2011 , we predicted that lvPPA patients would have elevated tau uptake in language areas, including lefthemisphere posterior temporal, inferior parietal, and inferior frontal cortices; furthermore, we predicted that language task performance across all phenotypes would be negatively associated with SUVR in 
| R E SU LTS
3.1 | Domain-specific cognitive differences
Patients' cognition was marked by domain-specific cognitive deficits associated with their clinical phenotypes ( Table 2 ). As predicted, lvPPA patients had the lowest mean language score, followed by PCA and aAD patients. The mean visuospatial score was lowest for PCA patients, followed by aAD and lvPPA patients. Memory scores were lowest for the aAD group, followed by PCA and lvPPA patients. 
| Regional tau accumulation by phenotype
Group-average SUVR maps (Figure 1 ) revealed differential uptake of 18 F-flortaucipir in brain areas associated with each group's distinct phenotype and profile of cognitive impairment. In the lvPPA group uptake was heavily left lateralized, with foci in the left superior and middle temporal gyri, left precuneus, and bilateral supramarginal gyri (Table 3 ).
The PCA group exhibited the most extensive pattern of uptake among the three groups, with peaks throughout bilateral medial parietal and posterior occipito-temporal areas. Uptake in the aAD group was similar to that of the PCA group, with peak uptake in left precuneus and posterior cingulate; right posterior superior temporal and inferior parietal areas; and bilateral middle temporal areas. The results of voxelwise between-group t-tests are shown in Figure 2 . LvPPA patients had greater uptake than aAD patients in the left middle, inferior, and anterior superior temporal gyri. The greatest uptake difference between lvPPA and aAD was observed at x 5 247, y 5 247, z 5 228 (Table 4) and on-target regions. Significant correlations for both proximal and distal regions were expected from this series of tests, due to common inter-subject effects throughout the brain; accordingly, correlations were corrected for multiple comparisons using Holm's procedure (Hochberg & Benjamini, 1990) . Choroid plexus and substantia nigra labels were not present in the Mindboggle label atlas employed here. 
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independent patient cohort of the same phenotype (Supporting Information Figure S11 ).
| Sparse regression results
Sparse regression models yielded 3 spatial components (eigenvectors) associated with patients' language, visuospatial, and memory performance ( Figure 3 ). Language performance was associated with voxels in the anterior portion of the left superior temporal gyrus; the coordinates of peak loadings on this eigenvector are given in Table 5 . Visuospatial performance was associated with a cluster in the right lingual gyrus. In the memory domain, the associated eigenvector included portions of right inferior temporal gyrus, cuneus, hippocampus, and amygdala.
Mean SUVRs by phenotype are shown for each of these 3 eigenvectors in Figure 4 . SUVR data projected onto these three eigenvectors provided more accurate models of patients' cognitive scores than predictions based on anatomical ROIs (Figures 5 & 6) . Projections on the language eigenvector were significantly correlated with language scores (R 5 0.82; 95% c.
i.: 0.50-0.94; p < .001); by comparison, the best ROI-based prediction (Table 6) 
| D ISC USSION
In the current study, we assessed and middle frontal gyri (Mesulam et al., 2014b) . LvPPA due to AD is characterized by greater accumulation of pathology in superior temporal cortex than in lvPPA cases with non-AD pathology (Giannini et al., 2017) . The superior and middle temporal gyri have been proposed as components of a ventral language pathway involved in a number of speech-related functions (Friederici & Gierhan, 2013) , including repetition (Dehaene-Lambertz et al., 2006) , which is significantly impaired in lvPPA (Gorno-Tempini et al., 2008 , 2011 . This behavioral association has been validated outside the context of AD: Leff et al. (2009) found that in stroke patients, a broad extent of superior temporal cortex was associated with forward digit span, which is more severely impaired in patients with lvPPA due to AD than lvPPA due to FTLD pathology. Furthermore, in a longitudinal study of lvPPA patients, atrophy in the left posterior temporal and parietal cortices was accompanied by decrements not only in the repetition and comprehension of whole sentences, but also of single words (Rohrer et al., 2013) . Published criteria for imaging-assisted diagnosis of lvPPA thus highlight atrophy in posterior temporal and inferior parietal cortices as the anatomical signature of lvPPA (Gorno-Tempini et al., 2011) . In right hemisphere parietal, occipital, and posterior temporal areas, lvPPA patients had less uptake than PCA and aAD patients, consistent with the left-hemisphere lateralization of disease in this syndrome. LvPPA patients also had notably low uptake in early visual areas, combined with normal performance on visuospatial tasks.
Of the three phenotypes, PCA patients appeared to have the highest and most widespread uptake throughout the neocortex. This pattern was centered around posterior lateral and medial parietal and occipital cortices. These findings are thus consistent with postmortem examinations of patients with PCA due to AD, which reveal dense neurofibrillary tangles (Tang-Wai et al., 2004) and gliosis (Tom, Cummings, & Pollak, 1998) in occipital cortex. These same areas demonstrate hypoperfusion (Kas et al., 2011) and atrophy in neuroimaging studies (Whitwell et al., 2007) . Tracer uptake was elevated in portions of both the ventral and dorsal visual streams, which are both affected in PCA (McMonagle et al., 2006) , leading to symptoms that can involve both basic and complex visuospatial function (Crutch et al., 2012) .
In aAD cases, the anatomical distribution of uptake was similar to that reported by Schwarz et al. (2016) , with peak uptake in the precuneus, lateral parietal cortices, and occipito-temporal cortex. In contrast to the older AD patients studied by Schwarz and colleagues, however, aAD patients in the current study had relatively lower tracer uptake in the hippocampus and MTL. This finding is consistent with relative sparing of the hippocampus and MTL from tau pathology in early-onset AD (Whitwell et al., 2012) . In the neocortex, aAD patients' uptake patterns ( Figure 1 ) recapitulated postmortem studies of aAD, which report that neurofibrillary tau accumulates more densely in parietal and occipitotemporal association cortices than in primary visual, motor, and somatosensory cortices (Arnold et al., 1991; Braak et al., 2006) . Disease in temporal, occipital, and parietal cortices is common in more advanced stages of amnestic AD (Braak et al., 2006 , Dickerson et al., 2009 ), resulting in visuospatial and visuoconstructional deficits (Gross et al., 2012; Heindel, Festa, Ott, Landy, & Salmon, 2013; Libon, Swenson, Barnoski, & Sands, 1993) as well as language deficits (Ahmed, Haigh, F-flortaucipir uptake in parietal-occipital cortex (Cho et al., 2017) , one of the principal areas affected by disease in PCA.
The current results thus provide converging evidence for distinct anatomical distributions of tau across atypical AD phenotypes and are broadly similar to recent studies examining 18 F-flortaucipir uptake in atypical AD Xia et al., 2017) . These results emphasize the distinct nature of non-amnestic variants of AD, and the important role of apparent tau pathology in determining patient phenotype. Indeed, these patterns of tau uptake during life reflect the regional pathological burden of tau seen at autopsy in non-amnestic variants of AD (Gefen et al., 2012; Giannini et al., 2017; Whitwell et al., 2012 ). Although we have demonstrated phenotypic differences in uptake, more research is needed to establish and confirm clinically significant uptake thresholds for this tracer. It will be particularly interesting to determine anatomical markers where tracer uptake optimally distinguishes between PCA and early-onset amnestic AD patients.
| Tau PET associations with cognition
We used sparse regression models to identify areas of uptake associated with patients' cognitive performance. The current analysis identified anatomically distinct correlates of language, visuospatial, and memory performance, and the three phenotypes demonstrated significant uptake differences within these regions. Language performance was best predicted by uptake in the anterior portion of the left superior temporal gyrus, which accounted for 67% of the variance in patients' scores. These results are consistent with previous 18 F-flortaucipir studies reporting strong laterality in uptake for lvPPA patients Pascual & Masdeu, 2016) , reflecting a disease distribution that selectively affects a left-lateralized language processing network (Price, 2010) .
We note that lvPPA patients' peak uptake was not in the anterior temporal location occupied by the language-related eigenvector.
Rather, peak uptake occurred in more posterior regions of the superior and middle temporal gyri (see Figure 1 and Table 3 ), which are commonly reported in neuroimaging studies of lvPPA (Gorno-Tempini et al., 2004 , 2011 Grossman, 2010) . Because all three phenotypes had widespread uptake in more posterior portions of temporal cortex, it is possible that this region was not an effective marker for predicting individual and phenotypic differences in patients' language performance. In contrast, lvPPA patients had elevated SUVR in the left anterior superior temporal eigenvector (Figure 4) . Pathology in this area may have incrementally worsened lvPPA patients' language performance. Indeed, left
anterior temporal lobe atrophy in Alzheimer's disease has been associated with deficits on the Boston Naming Test (Domoto-Reilly, Sapolsky, Brickhouse, & Dickerson, 2012; Grossman et al., 2004) , which was included in our composite language score. However, we note that the language-related eigenvector was located posterior to regions associated with semantic memory deficits in semantic-variant primary progressive aphasia (Patterson et al., 2007) and did not comprise ventral anterior temporal cortex, which has been associated with high-order perceptual and conceptual processing (Harry, Umla-Runge, Lawrence, Graham, & Downing, 2016 , Wright, Randall, Clarke, & Tyler, 2015 .
This result differs from voxelwise regressions reported by Ossenkoppele et al. (2016) , in which language performance appeared to be most strongly associated with the left temporal pole. Overall, results suggest that the precise focus of disease in the anterior temporal lobe may be useful in differentiating between lvPPA due to different underlying pathologies or discriminating different primary progressive aphasias.
Such discrimination analyses may be additionally affected by 18 F-flortaucipir's differential affinity for 3-and 4-repeat isoforms of tau (Marqui e et al., 2015; Sander et al., 2016) . We note that patients in the current study were right-handed, with the exception of 2 PCA patients and 1 aAD patient with relatively little language impairment (scores of 20.53, 20.41, and 0.12, respectively) . It is thus unlikely that intersubject differences in language function lateralization affected language-related associations; however, in studies involving significant language impairment in left-handed or ambidextrous individuals, right temporal tau accumulation should also be assessed.
Of the three cognitive domains investigated, visuospatial function was most closely associated with tracer uptake. The visuospatial eigenvector explained 85% of the variance in cognitive scores and was local- and PCA is associated with ventral and dorsal stream structural changes that can occur either in isolation or concurrently within an individual patient (Migliaccio et al., 2012) . Moreover, recent consensus criteria for PCA diagnosis allow for subtypes of this syndrome that differ in the lateralization of disease (Crutch et al., 2017) . Heterogeneity in the distribution of tau pathology may thus account for the fact that The appearance of the cuneus in the memory-related eigenvector may also be due to the inclusion of two patients in the aAD group who initially presented with PCA. Finally, the memory-related eigenvector included a cluster that spanned the border between right hippocampus and amygdala, suggesting a role for the medial temporal lobe role in patients' episodic memory deficits; such deficits were observed in aAD patients as well as one PCA patient. However, memory scores were not associated with uptake averaged across the whole hippocampus or whole entorhinal cortex, further suggesting that tau accumulation in different MTL subregions was heterogeneously related to memory performance. Overall, uptake in MTL areas was considerably lower than in the neocortex and did not differ by phenotype. We additionally note that in both the current study and that of Ossenkoppele et al. (2016) , voxelwise associations between memory performance and MTL tracer uptake were observed at a statistical threshold of p < .05 but not p < .01, uncorrected for multiple comparisons. These cross-study similarities suggest a consistent but relatively modest association of MTL tau with memory deficits in atypical AD, possibly driven by the subset of amnestic patients in both cohorts. In contrast, early-onset and nonamnestic AD variants have less MTL atrophy, more widespread neocortical tau accumulation, and preserved episodic memory (Mendez et al., 2012; Murray et al., 2011; Whitwell et al., 2012) .
The current results demonstrate that sparse regression can effectively model phenotypic differences in domain-specific cognitive performance. The neuroanatomical distribution of 
| Limitations
The present study provides promising initial results regarding the anatomical specificity of 18 F-flortaucipir imaging and its association with patients' cognitive symptoms. However, several factors limit the interpretation of our results and provide motivation for a larger replication effort. First, the present study examined a relatively small cohort of amnestic and non-amnestic AD cases, and aspects of PET imaging results may be dependent on the particular individuals included. For example, the aAD patients whom we imaged had younger disease onsets (mean onset 5 58 years old) than in typical amnestic AD and are thus not representative of typical late-onset amnestic AD (Migliaccio et al., 2015) . It is possible that an amnestic cohort with later disease onset would have greater tau accumulation in the hippocampus and MTL. Second, sparse spatial decomposition of 18 F-flortaucipir data may result in different eigenvectors depending on the sample size and relative frequencies of different AD phenotypes; thus, the specific eigenvectors generated in the present study should be applied to other datasets only with great caution. Third, patients were grouped according to their phenotype at the time of PET imaging; thus, patients with clinically-observed memory impairments were classified as aAD, whether their initial presentation had been amnestic or not. This approach was chosen to highlight differences in cognitive performance and tau pathology at the time of imaging. In contrast, for analyses that focus on the evolution of clinical symptoms or anatomical progression of disease over time, it may be more appropriate to group patients according their syndrome at initial assessment: in this scenario, a patient who initially presented with PCA but later developed memory deficits would be grouped with other, non-amnestic PCA patients. The current patient groupings thus represent one approach to phenotypic heterogeneity in AD and are not meant to imply that PCA patients who subsequently develop memory deficits follow the same disease course as purely amnestic AD patients. Fourth, the present study did not compare the ability of PET tau and amyloid imaging results to account for clinical symptoms, nor did it consider possible interactions between tau and amyloid pathology (Ittner & G€ otz, 2011; see also Pontecorvo et al., 2017) . Fifth, tau PET imaging data from cognitively normal controls were not available. Although we report sparse eigenvectors that comprise known foci of disease in atypical AD syndromes, we were unable to assess relationships between PET data and cognition across both controls and patients. Including such a control group would allow us to confirm the absence of tracer uptake in controls and thus strengthen the case for associations between regional tracer uptake and domain-specific cognitive impairment. Sixth, the full extent of variation in 18 F-flortaucipir's binding properties remains an area of ongoing research. Uptake is known to differ according to tau isoform (Lowe et al., 2016; Sander et al., 2016) ; and a diversity of posttranslational mechanisms, including not only phosphorylation but also acetylation, methylation, and other changes (Goedert, Eisenberg, & Crowther, 2017; Martin, Latypova, & Terro, 2011; Morris et al., 2015) may contribute to patient-specific differences in uptake. Finally, definitive diagnosis of AD pathology can only be secured postmortem, and we cannot entirely rule out the possibility of co-morbid pathologies.
However, patients in the current study were screened for indications of vascular disease, and differential diagnoses (e.g., frontotemporal dementia and corticobasal syndrome) were considered in clinical consensus meetings involving multiple neurologists (DW, DI, and MG).
Moreover, CSF data consistent with AD pathology for all patients with available data.
| CON CL U S I ONS
With these caveats in mind, the current study demonstrates that 
